Breast Cancer News

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.

Researchers have developed an AI model capable of using an inexpensive, easy-to-obtain chromatin image to determine the stage of ductal carcinoma.

Breastfeeding appeared safe in women with hormone receptor–positive early breast cancer who temporarily interrupted treatment to attempt pregnancy, according to results from the POSITIVE trial presented at ESMO Congress.

Women who want breast reconstruction after mastectomy can undergo a shorter radiation therapy regimen without significantly increasing their risk for complications, according to results of a randomized phase 3 trial.

Olanzapine reduced severe nausea more effectively than prochlorperazine for patients with refractory symptoms after chemotherapy, according to results of a randomized phase 3 trial.

Women with breast cancer are at risk for lymphedema long after their treatment concludes, according to study findings.

HER2-positive breast cancer has become one of the most treatable breast cancer types among patients of all ages, including those aged 40 years and younger.

Adjuvant radiotherapy reduced risk for local recurrence for a decade among women with early breast cancer who underwent breast-conserving surgery, results of a randomized phase 3 trial showed.

Datopotamab deruxtecan failed to extend OS vs. chemotherapy for adults with advanced breast cancer, according to the agent’s manufacturer.